Publications by authors named "Michael Bottorff"

Claim this Profile
A
A Response to: Letter to the Editor Regarding "Critical Differences Between Dietary Supplement and Prescription Omega-3 Fatty Acids: a Narrative Review".
Daniel E Hilleman, Barbara S Wiggins, Michael B Bottorff

Adv Ther· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Practical Insight Into Anticoagulation for an Aging Population.
Michael B Bottorff, Michael H Kim, Utibe R Essien, Chad Worz

Sr Care Pharm· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Critical Differences Between Dietary Supplement and Prescription Omega-3 Fatty Acids: A Narrative Review.
Daniel E Hilleman, Barbara S Wiggins, Michael B Bottorff

Adv Ther· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Commentary: Should Pharmacogenomic Evidence Be Considered in Clinical Decision Making? Focus on Select Cardiovascular Drugs.
Michael B Bottorff, David R Bright, David F Kisor

Pharmacotherapy· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The relationship between four health-related quality-of-life indicators and use of mammography and Pap test screening in US women.
Pranav K Gandhi, William M Gentry, Jeffery L Kibert, Erica Y Lee, Whitney Jordan, Michael B Bottorff

Qual Life Res· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness analysis of allopurinol versus febuxostat in chronic gout patients: a U.S. payer perspective.
Pranav K Gandhi, William M Gentry, Qinli Ma, Michael B Bottorff

J Manag Care Spec Pharm· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Educational outcomes necessary to enter pharmacy residency training.
Elizabeth Kelly Hester, Sarah E McBane, Michael B Bottorff, Tristan A Carnes, Kamila Dell

Pharmacotherapy· January 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A clinician's guide to statin drug-drug interactions.
Kenneth A Kellick, Michael Bottorff, Peter P Toth, The National Lipid Association's Safety Task Force

J Clin Lipidol· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Alternative viewpoint: preparation for residency.
Katherine K Knapp, Károly Mészáros, Paul C Goldsmith, Gordon C McCarter, Elizabeth Kelly Hester, Michael B Bottorff

Pharmacotherapy· August 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Investigation of pegloticase-associated adverse events from a nationwide reporting system database.
William M Gentry, Michael P Dotson, Brian S Williams, Melissa Hartley, Kristen R Stafford, Michael B Bottorff

Am J Health Syst Pharm· May 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dabigatran-dronedarone interaction in a spontaneous reporting system.
Pranav K Gandhi, William M Gentry, Michael B Bottorff

J Am Pharm Assoc (2003)· February 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cardiovascular thromboembolic events associated with febuxostat: investigation of cases from the FDA adverse event reporting system database.
Pranav K Gandhi, William M Gentry, Michael B Bottorff

Semin Arthritis Rheum· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Thrombotic events associated with C1 esterase inhibitor products in patients with hereditary angioedema: investigation from the United States Food and Drug Administration adverse event reporting system database.
Pranav K Gandhi, William M Gentry, Michael B Bottorff

Pharmacotherapy· October 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antiplatelet therapy in patients with unstable angina and non-ST-segment-elevation myocardial infarction: findings from the CRUSADE national quality improvement initiative.
Michael B Bottorff, Edith A Nutescu, Sarah Spinler

Pharmacotherapy· August 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Role of the pharmacist.
Michael Bottorff

Pharmacotherapy· December 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Statin safety and drug interactions: clinical implications.
Michael B Bottorff

Am J Cardiol· April 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quality improvement in the continuum of care: impact of atherothrombosis in managed care pharmacy.
Michael R Toscani, Rajendra Makkar, Michael B Bottorff

J Manag Care Pharm· November 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Statin safety: what to know.
Michael B Bottorff

Am J Geriatr Cardiol· August 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
New roles for antiplatelet agents in treatment of atherothrombotic diseases.
Michael B Bottorff

J Am Pharm Assoc (2003)· May 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First MI and NSAIDs. Commentary: Inhibition of clinical benefits of aspirin on first myocardial infarction by nonsteroidal anti-inflammatory drugs.
Michael Bottorff

Consult Pharm· May 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Underidentification and undertreatment issues.
Michael B Bottorff

J Manag Care Pharm· December 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treating dyslipidemic patients with lipid-modifying and combination therapies.
Chad R Worz, Michael Bottorff

Pharmacotherapy· May 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combination antiplatelet therapy: implications for pharmacists.
Robert L Talbert, Sarah A Spinier, Jean M Nappi, Michael B Bottorff

J Am Pharm Assoc (Wash)· January 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combination antiplatelet therapy: implications for pharmacists.
Robert L Talbert, Sarah A Spinler, Jean M Nappi, Michael B Bottorff

Pharmacotherapy· October 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis